Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY as the first and only T-cell engaging bispecific antibody treatment in Japan of adult patients with certain types of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy. Epcoritamab is being co-developed by Genmab and AbbVie (ABBV) as part of the companies’ oncology collaboration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GMAB:
- Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab downgraded to Sector Perform from Outperform at RBC Capital
- Seagen, Genmab announce Phase 3 innovaTV 301 trial met primary endpoint of OS